In the latest trading session, Hologic (HOLX) closed at $80.46, marking a -0.46% move from the previous day.
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HOLX's fiscal 2024 fourth-quarter results are expected to reflect a solid performance of the Diagnostics business, led by the base Molecular franchise.
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The latest trading day saw Hologic (HOLX) settling at $81.15, representing a -0.51% change from its previous close.
Hologic's upcoming fourth-quarter fiscal 2024 financial report is expected to reflect strength in core franchises.
Hologic Inc. President and CEO Steve MacMillan joins ‘Mornings with Maria' to discuss his company's latest technological strides in women's health.
On Monday, Hologic Inc HOLX agreed to acquire Gynesonics, Inc. for approximately $350 million.
Hologic enters Breast Cancer Awareness Month with the launch of the BustTheMyth campaign. This campaign is aimed at busting myths regarding breast health.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.